These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10686012)

  • 1. Blood component recalls in the United States, 1998.
    Ramsey G; Sherman LA
    Transfusion; 2000 Feb; 40(2):253-4. PubMed ID: 10686012
    [No Abstract]   [Full Text] [Related]  

  • 2. Blood component recalls in the United States.
    Ramsey G; Sherman LA
    Transfusion; 1999 May; 39(5):473-8. PubMed ID: 10335996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood component recalls.
    Bozzo T
    Transfusion; 1999 May; 39(5):439-41. PubMed ID: 10335990
    [No Abstract]   [Full Text] [Related]  

  • 4. Blood component recalls and market withdrawals: frequency, reasons, and management in the United States.
    Ramsey G
    Transfus Med Rev; 2013 Apr; 27(2):82-90. PubMed ID: 23375736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing recalls and withdrawals of blood components.
    Ramsey G
    Transfus Med Rev; 2004 Jan; 18(1):36-45. PubMed ID: 14689376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.
    Fed Regist; 1996 Sep; 61(175):47413-23. PubMed ID: 10160337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood product recalls in the United States.
    McCullough J; Riley E; Lindgren B; Pulkrabek S; Hall R; Riley W
    Transfusion; 2014 Sep; 54(9):2276-82. PubMed ID: 24863173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare and Medicaid programs; hospital standard for potentially HIV infectious blood and blood products--HCFA. Final rule.
    Fed Regist; 1996 Sep; 61(175):47423-34. PubMed ID: 10160338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Universal WBC reduction.
    Nightingale SD;
    Transfusion; 2001 Oct; 41(10):1306-9. PubMed ID: 11606833
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA regulation of human tissue: implications for skin banks and burn centers.
    Kagan RJ
    J Burn Care Rehabil; 2000; 21(4):353-7. PubMed ID: 10935818
    [No Abstract]   [Full Text] [Related]  

  • 11. Evidence-based recommendations for the use of WBC-reduced cellular blood components.
    Ratko TA; Cummings JP; Oberman HA; Crookston KP; DeChristopher PJ; Eastlund DT; Godwin JE; Sacher RA; Yawn DH; Matuszewski KA;
    Transfusion; 2001 Oct; 41(10):1310-9. PubMed ID: 11606834
    [No Abstract]   [Full Text] [Related]  

  • 12. Advancing risk assessment for emerging infectious diseases for blood and blood products: proceedings of a public workshop.
    Gallagher LM; Ganz PR; Yang H; Kessler DA; O'Brien SF; Custer BS; Busch MP; Dodd RY; Stramer SL; Walderhaug MO; Forshee RA; Williams AE; Epstein JS; Anderson SA
    Transfusion; 2013 Feb; 53(2):455-63. PubMed ID: 22845334
    [No Abstract]   [Full Text] [Related]  

  • 13. The good, the bad & the ugly: the political economy of the blood products industry.
    Dubin CS
    Common Factor; 1998 Oct; (No 12):4-5, 8. PubMed ID: 11365880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The computer or electronic crossmatch.
    Butch SH; Oberman HA
    Transfus Med Rev; 1997 Oct; 11(4):256-64. PubMed ID: 9345707
    [No Abstract]   [Full Text] [Related]  

  • 15. Revisiting Factor VIII cases: is it time for an agency adjudication system?
    Su YC
    Food Drug Law J; 2008; 63(4):943-61. PubMed ID: 19601390
    [No Abstract]   [Full Text] [Related]  

  • 16. ANA publishes brochure on bloodborne diseases.
    Am Nurse; 1993 Feb; 25(2):2. PubMed ID: 8382456
    [No Abstract]   [Full Text] [Related]  

  • 17. Should the FDA mandate that autologous units drawn and transfused within a single institution be tested for markers of infectious disease?
    Perkins J; Kaminer L; Kruskall M; Cannon M; Uhl L; Dzik W; Silver H; O'Neill M; Popovsky M; King K; Ness P; AuBuchon J; Shapiro A; Yomtovian R; Petz LD
    Transfusion; 2000 Jun; 40(6):752-4. PubMed ID: 10865000
    [No Abstract]   [Full Text] [Related]  

  • 18. Physician liability and drug recalls.
    Johnson LJ
    Med Econ; 2001 Sep; 78(17):118. PubMed ID: 11573390
    [No Abstract]   [Full Text] [Related]  

  • 19. Making sense of the use of blood and blood products.
    Dodsworth H
    Nurs Times; 1995 Jan 4-11; 91(1):25-7. PubMed ID: 7838744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mandatory infectious disease marker testing of autologous blood--a flawed proposal.
    Yomtovian R
    Transfusion; 1996 Jan; 36(1):85-6. PubMed ID: 8607164
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.